Opinion|Videos|December 9, 2024
Resources and Education for Operationalizing Bispecifics
Panelists discuss how infrastructure including specialized staff training, updated protocols, enhanced monitoring systems, and comprehensive educational resources for health care providers is essential for institutions to successfully implement and optimize bispecific antibody therapies while ensuring patient safety and treatment efficacy.
Advertisement
Video content above is prompted by the following
- What resources can institutions looking to provide bispecific antibodies utilize to overcome these challenges discussed thus far?
- What further education and information would be helpful for stakeholders regarding operationalizing bispecific antibodies?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IVIG Therapy Reduced Infections by 67% in Patients With Multiple Myeloma
September 19th 2025
- IMS 2025: Shifting Immunotherapies to Outpatient Care for Multiple Myeloma
September 19th 2025
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
4
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
5